GenSight Biologics

105 articles about GenSight Biologics

• GenSight Biologics to Host KOL Event on June 12, 2018

  5/21/2018

  GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that it will host a KOL Event on June 12, 2018 in New York City from 8 a.m. – 10:30 a.m. ET.

• GenSight Biologics announces topline results from REVERSE Phase III clinical trial of GS010 in patients with Leber Hereditary Optic Neuropathy (LHON)

  4/3/2018

  GS010 reported to be safe and well-tolerated A clinically meaningful improvement of +11 ETDRS letters reported in the 37 subjects in both eyes Unexpected improvement in the untreated eye suggests a bilateral treatment effect to be further investigated SD-OCT demonstrated statistically significant preservation of both retinal ganglion cells and retinal fiber layer in treated eyes vs. untreated eyes

• GenSight Biologics Announces Publication of Positive Data from Phase I/II Trial and Long-Term Follow-up of GS010 in Ophthalmology, the Journal of the American Academy of Ophthalmology

  2/20/2018

  The study demonstrated that GS010 (rAAV2/2-ND4) is safe and well tolerated 2 years after a single unilateral intravitreal administration.

• GenSight Biologics Appoints Julio Benedicto as Vice President of Marketing

  1/25/2018

  Mr. Benedicto brings over 20 years of experience as a strategy consultant in life sciences, both in Europe and the United States.

• GenSight Biologics Receives MHRA Approval to Initiate Phase I/II PIONEER Clinical Trial of GS030 Gene Therapy in Retinitis Pigmentosa

  1/10/2018

  The primary outcome analysis will be the safety and tolerability at one year post-injection.

• GenSight Biologics Reports Positive Long-Term Visual Acuity Gains and Safety Results From Phase I/II Study of GS010 for the Treatment of Leber Hereditary Optic Neuropathy (LHON)

  12/7/2017

  In the study, five cohorts of three subjects were administered an increasing dose of GS010 via a single intravitreal injection in the eye more severely affected by the disease.

• GenSight Biologics to Participate in Multiple Conferences in November

  11/6/2017

  GenSight Biologics today announced that members of its management team will participate in the following industry, medical and investor conferences: OIS, AAO, and Stifel Healthcare Conferences.

• GenSight Biologics Appoints Barrett Katz as Chief Medical Officer

  10/25/2017

  Dr. Katz replaces Mohamed Genead, M.D., who resigned from the position for personal reasons.

• GenSight Biologics To Present Data On GS010 And GS030 At The 2017 Congress Of The European Society Of Gene & Cell Therapy

  10/17/2017

  GenSight Biologics today announced multiple data presentations at the Congress of the European Society of Gene and Cell Therapy (ESGCT) in Berlin, Germany, October 17-20, 2017.

• GenSights Integrates The Cac Small, Cac Mid And Small And Cac All-Tradable Euronext Indexes

  9/19/2017

• GenSight Completes Enrollment Of RESCUE Phase III Study Of GS010 In The Treatment Of Leber’s Hereditary Optic Neuropathy

  8/1/2017

• GenSight Reports Long-Term Positive Safety And Visual Acuity Results At Week 96 In Phase I/II Study Of GS010 For The Treatment Of Leber’s Hereditary Optic Neuropathy (LHON)

  6/14/2017

• GenSight Appoints Mohamed Genead As Chief Medical Officer

  5/4/2017

• Backed By Two Drug Powerhouses, GenSight Alum Launches New Biotech With $40 Million

  5/4/2017

• GenSight Biologics Reports Full Year 2016 Financial Results

  3/13/2017

• GenSight Biologics Completes Enrollment Of REVERSE Phase III Study Of GS010 In The Treatment Of Leber’s Hereditary Optic Neuropathy

  2/21/2017

• GenSight Biologics Receives FDA Orphan Drug Designation For GS030 In Retinitis Pigmentosa

  1/31/2017

• GenSight Biologics Reports Sustained Visual Acuity Gain At 78 Weeks In Its Phase I/II Study With GS010 For The Treatment Of Leber’s Hereditary Optic Neuropathy (LHON)

  12/20/2016

• GenSight Biologics Receives Approval To Include Teenage Patients In RESCUE And REVERSE Phase III Trials With GS010 In Leber’s Hereditary Optic Neuropathy

  9/8/2016

• GenSight Biologics Receives Orphan Drug Designation And Advanced Therapy Medicinal Product Classification In Europe For GS030 In Retinitis Pigmentosa

  9/1/2016